Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Kisplyx 10mg capsules
0801050BVBCABAB
|
Kisplyx | Lenvatinib | Malignant Disease and Immunosuppression | No data available |
|
Kisplyx 4mg capsules
0801050BVBCAAAA
|
Kisplyx | Lenvatinib | Malignant Disease and Immunosuppression | No data available |
|
Kisqali 200mg tablets
0801050CRBBAAAA
|
Kisqali | Ribociclib | Malignant Disease and Immunosuppression | No data available |
|
Lanreotide 60mg/0.3ml inj pre-filled syringes
0803043P0AAABAB
|
Lanreotide | Lanreotide | Malignant Disease and Immunosuppression | No data available |
|
Lanreotide 90mg/0.3ml inj pre-filled syringes
0803043P0AAACAC
|
Lanreotide | Lanreotide | Malignant Disease and Immunosuppression | No data available |
|
Lanvis 40mg tablets
0801030T0BBAAAA
|
Lanvis | Tioguanine | Malignant Disease and Immunosuppression | No data available |
|
Lapatinib 250mg tablets
0801050ATAAAAAA
|
Lapatinib | Lapatinib | Malignant Disease and Immunosuppression | No data available |
|
Ledaga 160micrograms/g gel
0801010W0BCAAAB
|
Ledaga | Chlormethine hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Lederfolin 350mg/35ml solution for injection vials
0801000I0BFABBE
|
Lederfolin | Calcium folinate | Malignant Disease and Immunosuppression | No data available |
|
Lemtrada 12mg/1.2ml concentrate for inf vials
0802030E0BCAAAB
|
Lemtrada | Alemtuzumab | Malignant Disease and Immunosuppression | No data available |
|
Lenalidomide 10mg capsules
0802040Y0AAABAB
|
Lenalidomide | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Lenalidomide 15mg capsules
0802040Y0AAACAC
|
Lenalidomide | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Lenalidomide 2.5mg capsules
0802040Y0AAAEAE
|
Lenalidomide | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Lenalidomide 20mg capsules
0802040Y0AAAGAG
|
Lenalidomide | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Lenalidomide 5mg capsules
0802040Y0AAAAAA
|
Lenalidomide | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Lenalidomide 7.5mg capsules
0802040Y0AAAFAF
|
Lenalidomide | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Lenvatinib 10mg capsules
0801050BVAAABAB
|
Lenvatinib | Lenvatinib | Malignant Disease and Immunosuppression | No data available |
|
Lenvatinib 4mg capsules
0801050BVAAAAAA
|
Lenvatinib | Lenvatinib | Malignant Disease and Immunosuppression | No data available |
|
Lenvima 10mg capsules
0801050BVBBABAB
|
Lenvima | Lenvatinib | Malignant Disease and Immunosuppression | No data available |
|
Lenvima 4mg capsules
0801050BVBBAAAA
|
Lenvima | Lenvatinib | Malignant Disease and Immunosuppression | No data available |
|
Leukeran 2mg tablets
0801010F0BBAAAA
|
Leukeran | Chlorambucil | Malignant Disease and Immunosuppression | No data available |
|
Leukeran 5mg tablets
0801010F0BBABAB
|
Leukeran | Chlorambucil | Malignant Disease and Immunosuppression | No data available |
|
Leuprorelin 11.25mg inj vials
0803042N0AAABAB
|
Leuprorelin acetate | Leuprorelin acetate | Malignant Disease and Immunosuppression | No data available |
|
Leuprorelin 22.5mg inj vials
0803042N0AAAEAE
|
Leuprorelin acetate | Leuprorelin acetate | Malignant Disease and Immunosuppression | No data available |
|
Leuprorelin 3.75mg inj vials
0803042N0AAAAAA
|
Leuprorelin acetate | Leuprorelin acetate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.